Evidence map›Paper›PMID 30970027›Full record

ArticlePloS one2019

Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.

O E Bryzgunova, I A Zaporozhchenko, E A Lekchnov, E V Amelina, M Yu Konoshenko, S V Yarmoschuk, O A Pashkovskaya, A A Zheravin, S V Pak, E Yu Rykova and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

O E BryzgunovaThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.
I A ZaporozhchenkoThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.ORCID 0000-0001-9101-2207
E A LekchnovThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.
E V AmelinaFederal State Autonomous Educational Institution of Higher Education "Novosibirsk National Research University", Novosibirsk, Russia.
M Yu KonoshenkoThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.ORCID 0000-0003-2925-9350
S V YarmoschukThe Laboratory of Biomedical Technologies, Centre of New Medical Technologies,"E. Meshalkin National Medical Research Center" of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.
O A PashkovskayaThe Laboratory of Biomedical Technologies, Centre of New Medical Technologies,"E. Meshalkin National Medical Research Center" of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.
A A ZheravinThe Laboratory of Biomedical Technologies, Centre of New Medical Technologies,"E. Meshalkin National Medical Research Center" of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.
S V PakThe Laboratory of Biomedical Technologies, Centre of New Medical Technologies,"E. Meshalkin National Medical Research Center" of the Ministry of Health of the Russian Federation, Novosibirsk, Russia.
E Yu RykovaThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.
P P LaktionovThe Laboratory of Molecular Medicine, Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUMeshalkin National Medical Research Center · RUNovosibirsk State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urine of prostate cancer (PCa) carries miRNAs originated from prostate cancer cells as a part of both nucleoprotein complexes and cell-secreted extracellular vesicles. The analysis of such miRNA-markers in urine can be a convenient option for PCa screening. The aims of this study were to reveal miRNA-markers of PCa in urine and design a robust and precise diagnostic test, based on miRNA expression analysis. The expression analysis of the 84 miRNAs in paired urine extracellular vesicles (EVs) and cell free urine supernatant samples from healthy donors, patients with benign and malignant prostate tumours was done using miRCURY LNA miRNA qPCR Panels (Exiqon, Denmark). Sets of miRNAs differentially expressed between the donor groups were found in urine EVs and urine supernatant. Diagnostically significant miRNAs were selected and algorithm of data analysis, based on expression data on 24-miRNA in urine and obtained using 17 analytical systems, was designed. The developed algorithm of data analysis describes a series of steps necessary to define cut-off values and sequentially analyze miRNA expression data according to the cut-offs to facilitate classification of subjects in case/control groups and allows to detect PCa patients with 97.5% accuracy.

Indexed as

AgedAged, 80 and overAlgorithmsBiomarkers, TumorCase-Control StudiesData Interpretation, StatisticalExtracellular VesiclesGene Regulatory NetworksHumansMaleMicroRNAsMiddle AgedProstatic HyperplasiaProstatic NeoplasmsBiomarkers, TumorMicroRNAs

Identifiers

PMID30970027
PMCPMC6457524
OpenAlexW2938906210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.